Nanotechnology-enabled immunogenic cell death for improved cancer immunotherapy

Tumor immunotherapy has revolutionized the field of oncology treatments in recent years. As one of the promising strategies of cancer immunotherapy, tumor immunogenic cell death (ICD) has shown significant potential for tumor therapy. Nanoparticles are widely used for drug delivery due to their versatile characteristics, such as stability, slow blood elimination, and tumor-targeting ability. To increase the specificity of ICD inducers and improve the efficiency of ICD induction, functionally specific nanoparticles, such as liposomes, nanostructured lipid carriers, micelles, nanodiscs, biomembrane-coated nanoparticles and inorganic nanoparticles have been widely reported as the vehicles to deliver ICD inducers in vivo. In this review, we summarized the strategies of different nanoparticles for ICD-induced cancer immunotherapy, and systematically discussed their advantages and disadvantages as well as provided feasible strategies for solving these problems. We believe that this review will offer some insights into the design of effective nanoparticulate systems for the therapeutic delivery of ICD inducers, thus, promoting the development of ICD-mediated cancer immunotherapy.

Automated summary

Tumor immunotherapy, specifically tumor immunogenic cell death (ICD), has shown great potential for cancer therapy. Nanoparticles, such as liposomes, nanostructured lipid carriers, and inorganic nanoparticles, have been widely studied as vehicles for delivering ICD inducers. This review summarizes the strategies of different nanoparticles for ICD-induced cancer immunotherapy and discusses their advantages, disadvantages, and potential solutions. It aims to provide insights into the design of effective nanoparticulate systems for the therapeutic delivery of ICD inducers, ultimately promoting the development of ICD-mediated cancer immunotherapy.